{"id":54731,"date":"2023-03-10T22:03:12","date_gmt":"2023-03-10T21:03:12","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/"},"modified":"2023-03-10T22:03:12","modified_gmt":"2023-03-10T21:03:12","slug":"omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/","title":{"rendered":"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank"},"content":{"rendered":"
\n

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank.\n<\/p>\n

<\/a><\/p>\n

\nOmeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omeros does not have any assets on deposit with Silicon Valley Bank, nor does the company maintain any other financial relationship with the bank or its affiliated entities.\n<\/p>\n

\nAbout Omeros Corporation<\/b>\n<\/p>\n

\nOmeros is an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. Omeros\u2019 lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. Omeros\u2019 long-acting MASP-2 inhibitor OMS1029 is currently in a Phase 1 clinical trial. OMS906, Omeros\u2019 inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria (PNH), complement 3 (C3) glomerulopathy and one or more related indications. For more information about Omeros and its programs, visit www.omeros.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nJennifer Cook Williams
\n
Cook Williams Communications, Inc.
\n
Investor and Media Relations
\n
IR@omeros.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omeros does not have any assets on deposit with Silicon … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-54731","6":"format-standard","7":"category-industry"},"yoast_head":"\nOmeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omeros does not have any assets on deposit with Silicon ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-10T21:03:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230310005382\/en\/606373\/21\/Omeros_Logo_RGB_with_R.2014.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank\",\"datePublished\":\"2023-03-10T21:03:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/\"},\"wordCount\":250,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005382\\\/en\\\/606373\\\/21\\\/Omeros_Logo_RGB_with_R.2014.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/\",\"name\":\"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005382\\\/en\\\/606373\\\/21\\\/Omeros_Logo_RGB_with_R.2014.jpg\",\"datePublished\":\"2023-03-10T21:03:12+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005382\\\/en\\\/606373\\\/21\\\/Omeros_Logo_RGB_with_R.2014.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230310005382\\\/en\\\/606373\\\/21\\\/Omeros_Logo_RGB_with_R.2014.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/","og_locale":"en_US","og_type":"article","og_title":"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank - Pharma Trend","og_description":"SEATTLE–(BUSINESS WIRE)–Omeros Corporation (Nasdaq: OMER), in response to investor inquiries, is confirming that it has no banking or other financial relationship with Silicon Valley Bank. Omeros previously maintained a line of credit with Silicon Valley Bank, which the company allowed to expire in August 2022. Omeros does not have any assets on deposit with Silicon ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-10T21:03:12+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230310005382\/en\/606373\/21\/Omeros_Logo_RGB_with_R.2014.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank","datePublished":"2023-03-10T21:03:12+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/"},"wordCount":250,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230310005382\/en\/606373\/21\/Omeros_Logo_RGB_with_R.2014.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/","url":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/","name":"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230310005382\/en\/606373\/21\/Omeros_Logo_RGB_with_R.2014.jpg","datePublished":"2023-03-10T21:03:12+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230310005382\/en\/606373\/21\/Omeros_Logo_RGB_with_R.2014.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230310005382\/en\/606373\/21\/Omeros_Logo_RGB_with_R.2014.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/omeros-corporation-confirms-absence-of-financial-exposure-to-silicon-valley-bank\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=54731"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/54731\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=54731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=54731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=54731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}